Additional Information
Market: LSE
Sector: Pharmaceuticals & Biotechnology
EPIC: GSK
Latest Price: 1,340.50p  (-0.91% Descending)
52-week High: 1,706.00p
52-week Low: 1,296.50p
Market Cap: 65,011.14M
1 year chart More charts
Deal GSK Tax Free*
*subject to change and depends on individual circumstances.
1 day chart More charts
Advertisement
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
GlaxoSmithKline
www.gsk.com
Deal GlaxoSmithKline Tax Free* Losses can exceed
your initial deposit
*subject to change and depends on individual circumstances.

GlaxoSmithKline supplies an estimated seven per cent of the world's pharmaceutical market and has six major disease areas – asthma, virus control, infections, mental health, diabetes and digestive conditions.

Pdf

GlaxoSmithKline to invest £500m in UK manufacturing capacity

March 22 2012, 9:52am GlaxoSmithKline today confirmed plans to invest £500 million in its manufacturing network in the UK, which is expected to create 1,000 jobs

 

The corporate tax breaks announced in yesterday's budget speech by Chancellor George Osborne have borne fruit as GlaxoSmithKline (LON:GSK) confirmed plans to build its first manufacturing plant in the UK in 40 years.

The construction of the £350 million biopharmaceutical factory will kick off in 2014-15 with the facility expected to be operational in 2020.

The investment package announced by GSK today amounts to £500 million and includes £100 million for the group's two manufacturing sites in Scotland.

The investments will create 1,000 jobs in the UK, compensating for the 1,500 jobs lost last year when American drugmaker Pfizer shut down its research and development centre in Kent.

Furthermore, Glaxo is considering other investments in its UK manufacturing network, which it said should “create further jobs and reinforce the UK’s international competitiveness and as a world leader in life sciences”.

Investment in GSK’s manufacturing capacity at Ulverston could be doubled to £700 million, depending on the environment for innovations in the UK, the group added.

The confirmation from GSK came only a day after Chancellor George Osborne presented the budget for the 2012-13 fiscal year, which included corporate tax breaks such as the so-called patent box – a reduction in taxes imposed on patent-generated profits.

“The introduction of the patent box has transformed the way in which we view the UK as a location for new investments, ensuring that the medicines of the future will not only be discovered, but can also continue to be made here in Britain,” said GSK chief executive Andrew Witty.

Prime Minister David Cameron called the decision by GSK “excellent news”, adding that it will give a major boost to the UK economy.

“It shows why we are right to cut business tax and focus on making the UK a dynamic and competitive place that can attract exactly this type of high tech investment,” said Cameron.

“We have a world class life sciences industry, and I am determined not just to keep it here in the UK but significantly increase it too.”

 

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.